Ghassan Abou-Alfa, MD, MBA - Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches

This content has been developed for healthcare professionals only.
Patients who seek health information should consult with their
physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides,
and complete CME/MOC/AAPA/IPCE information, and to apply for
credit, please visit us at PeerView.com/AAU865. CME/MOC/AAPA/IPCE
credit will be available until February 18, 2025.


Calibrating Care Across the HCC Continuum: Guidance on Delivering
Effective Care With Modern Immunotherapy and Targeted Approaches


In support of improving patient care, this activity has been
planned and implemented by PVI, PeerView Institute for Medical
Education, and Blue Faery: The Adrienne Wilson Liver Cancer
Association. PVI, PeerView Institute for Medical Education, is
jointly accredited by the Accreditation Council for Continuing
Medical Education (ACCME), the Accreditation Council for Pharmacy
Education (ACPE), and the American Nurses Credentialing Center
(ANCC), to provide continuing education for the healthcare team.


SupportThis educational activity is
supported through independent educational grants from
AstraZeneca, Eisai Inc., Exelixis, Inc., Merck & Co., Inc.,
and Novocure, Inc.


Disclosure Policy
All relevant conflicts of interest have been mitigated prior to
the commencement of the activity.


Faculty/Planner
DisclosuresChair/Planner
Ghassan Abou-Alfa, MD, MBA, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Autem Therapeutics;
Berry Genomics; BioNTech; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; Incyte; Ipsen
Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Neogene
Therapeutics; NewBridge Pharmaceuticals; Novartis Pharmaceuticals
Corporation; Servier Laboratories; Tempus; Vector; and
Yiviva.
Grant/Research Support from Agenus Inc.; Arcus Biosciences, Inc.;
AstraZeneca; BioNTech; Bristol Myers Squibb; Elicio Therapeutics
Inc; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Helsinn Healthcare
SA; Parker Institute for Cancer Immunotherapy; Pertzye; Puma
Biotechnology, Inc.; QED Therapeutics; and Yiviva.


Faculty/Planner
Anthony El-Khoueiry, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Exelixis, Inc.; F.
Hoffmann-La Roche AG/Genentech, Inc.; Merck & Co., Inc.;
Qurient; and Senti Biosciences.
Grant/Research Support from Astex Pharmaceuticals; AstraZeneca;
Auransa Inc.; and Fulgent Pharma.


Faculty/Planner
Ahmed Omar Kaseb, MD, CMQ, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Eisai Inc.;
Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; and
Pfizer.
Grant/Research Support from Bristol Myers Squibb; Eisai Inc.;
Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; Pfizer;
and Tvardi Therapeutics.


Faculty/Planner
Stacey M. Stein, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Eisai Inc.; Exelixis,
Inc.; and Genentech, Inc.
Data Safety Monitoring Board for Aethlon Medical, Inc.and
Genentech, Inc.


Planning Committee and Reviewer
DisclosuresPlanners, independent reviewers, and
staff of PVI, PeerView Institute for Medical Education, do not
have any relevant financial relationships related to this CE
activity unless listed below.


Planner
Andrea Wilson Woods
President & Founder, Blue Faery


Andrea Wilson Woods has a financial interest/relationship or
affiliation in the form of:
Consultant for AstraZeneca and Humanise Health.